MFN Pricing: “More Fun to Navigate” - A European Roadmap to Success

Context Most-Favored Nation (MFN) pricing is characterized by uncertainty, particularly regarding how the Administration will steer it through Congress. However, we cannot wait for the legislative process to complete—doing nothing is not an option. Tim Wright, EVP at Genesis Research Group with 30 years of in-house and consulting experience, will provide a practical walk-through on how to plan for success, including key milestones and challenges along the way. Approach During the session, Tim will cover essential steps in establishing the US anchor price, including the role of value-based pricing, the importance of setting an early economically justifiable price, and the pros and cons of different US price options. He will then “fly across the Atlantic” to show how these planning steps can positively influence European strategic pricing and, importantly, what options manufacturers have to minimize price erosion risks from subsequent approvals. Learning Objectives By the end of the session, you will have: - A roadmap to help guide you through the uncharted territory of Most-Favored Nation pricing - A clear understanding of the implications for both biotechs and large pharma Who Should Attend Anyone responsible for pricing, market access, early commercial strategy, policy, or HEOR.

Sponsored by Corporate Partner, Genesis Research Group